دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 12,000,000 تومان- قیمت ویژه : 6,250,000تومان
دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 4,000,000 تومان- قیمت ویژه : 1,750,000تومان
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis.
doi : 10.1161/CIRCULATIONAHA.124.069323
Volume 152(10) pgs. 639-742,e88-e109 September 09, 2025
Defining Optimal Treatment Strategies for Bicuspid Aortic Valve Stenosis With Balloon- and Self-Expandable Transcatheter Heart Valves.
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.
Unique Role of Intracellular Perinuclear [beta]1-Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling.
Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction.
Adipose Tissue in and Around the Heart: Structural and Functional Insights From Cardiac Magnetic Resonance.
Dramatic and Puzzling Changes in All Waveforms: Unraveling an ECG Mystery.
AAV9-Mediated TNPO3 Overexpression in the Heart Rescues RBM20 Cardiomyopathy in Mice.
Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Speckle-Tracking Strain Echocardiography for the Assessment of Left Ventricular Structure and Function: A Scientific Statement From the American Heart Association.
